Otsuka Holdings Co., Ltd. (TYO:4578)
Japan · Delayed Price · Currency is JPY 10,610
+135 (1.29%)
At close: Mar 24, 2026
Otsuka Holdings Revenue
In the year 2025, Otsuka Holdings had annual revenue of 2.47T JPY with 5.97% growth. Otsuka Holdings had revenue of 650.15B in the quarter ending December 31, 2025, with 8.40% growth.
Revenue
2.47T
Revenue Growth
+5.97%
P/S Ratio
2.27
Revenue / Employee
65.39M
Employees
37,758
Market Cap
5.60T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.47T | 139.03B | 5.97% |
| Dec 31, 2024 | 2.33T | 311.29B | 15.42% |
| Dec 31, 2023 | 2.02T | 280.57B | 16.14% |
| Dec 31, 2022 | 1.74T | 239.72B | 16.00% |
| Dec 31, 2021 | 1.50T | 75.45B | 5.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Astellas Pharma | 2.06T |
| Daiichi Sankyo Company | 2.05T |
| Chugai Pharmaceutical | 1.26T |
| Ono Pharmaceutical | 509.35B |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Otsuka Holdings News
- 4 months ago - US FDA approves Otsuka's kidney disease drug - Reuters
- 6 months ago - Shares of Asian drugmakers drop after Trump threatens tariffs - Reuters